id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-3679-0014,FDA,FDA-2019-D-3679,Interacting With the Food and Drug Administration on Complex Innovative Trial Designs for Drugs and Biological Products; Guidance for Industry; Availability,Notice,Notice of Availability,2020-12-17T05:00:00Z,2020,12,2020-12-17T05:00:00Z,,2020-12-17T19:10:20Z,2020-27813,0,0,09000064849a443c
FDA-2019-D-3679-0015,FDA,FDA-2019-D-3679,Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products; Guidance for Industry,Other,Guidance,2020-12-17T05:00:00Z,2020,12,2020-12-17T05:00:00Z,,2024-11-12T23:26:26Z,,1,0,09000064849a5c00
FDA-2019-D-3679-0001,FDA,FDA-2019-D-3679,Interacting With the Food and Drug Administration on Complex Innovative Clinical Trial Designs for Drugs and Biological Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2019-09-23T04:00:00Z,2019,9,2019-09-23T04:00:00Z,2019-12-24T04:59:59Z,2019-12-24T02:01:28Z,2019-20494,0,0,0900006483fab277
FDA-2019-D-3679-0002,FDA,FDA-2019-D-3679,Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products Draft Guidance for Industry,Other,Guidance,2019-09-20T04:00:00Z,2019,9,2019-09-20T04:00:00Z,,2024-11-12T23:09:07Z,,1,0,0900006483fabf25